Shares of PROCEPT BioRobotics (NASDAQ: PRCT) tumbled 6.05% in after-hours trading on Tuesday, despite the surgical robotics company reporting better-than-expected third-quarter results. The sharp decline suggests that investors may be focusing on the company's forward guidance and potential growth concerns.

For the third quarter, PROCEPT BioRobotics reported revenue of $83.3 million, surpassing analysts' expectations of $80.9 million. The company's adjusted EBITDA loss of $7.4 million was also better than the estimated loss of $10.2 million. However, the company still posted a net loss of $21.4 million for the quarter.

While PROCEPT BioRobotics maintained its fiscal year 2025 revenue guidance of approximately $325.5 million, representing a 45% year-over-year growth, the company's newly issued fiscal year 2026 revenue guidance seems to have disappointed investors. The company projects 2026 revenue to be in the range of $410 million to $430 million, indicating a growth rate of 26% to 32% compared to the 2025 guidance. This potential slowdown in growth rate may be a key factor behind the stock's after-hours decline.

Despite the positive Q3 results and the company's continued expansion of its installed base of robotic systems, the market's reaction suggests that investors were expecting more aggressive growth projections for the coming year. As PROCEPT BioRobotics continues to navigate the competitive medical device landscape, investors will likely keep a close eye on the company's ability to maintain its growth trajectory and path to profitability.